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Background: Community-acquired pneumonia (CAP) is a common problem and the principal infection requiring 
hospitalization, but its treatment is complicated by the difficulty in microbiological diagnosis and the increasing 
incidence of antibiotic resistance among respiratory pathogens. The purpose of this paper is to present the main 
epidemiologic features of patients with CAP requiring hospitalization in our country. 
Methods: We enrolled three hundred and eighteen adult patients with CAP requiring hospitalization in seven large 
medical centers in Switzerland during two winter periods. The patients’ mean age was 70.4 years. This study describes 
the epidemiology of these patients. Clinical, radiologic and microbiological evaluations were performed at study entry 
during treatment, and at 4 weeks post-therapy. For microbiological diagnostic purposes, sputum culture, throat swab 
culture, PCR, blood cultures, Legionella urinary antigen and serologic evaluations were also performed. 
Results: Despite the higher mean age, the overall mortality rate was 8%, lower than in other comparable studies. 
The most common underlying diseases present at study entry were cardiac failure (23%) chronic obstructive pulmonary 
disease (20%) renal failure (15%) and diabetes (12%);40% of the patients were smokers. Although dyspnea, cough 
and positive pulmonary auscultation findings were present in about 90% of patients, fever >38”C was present in only 
64%. The most frequently isolated respiratory pathogens were Streptococcus pneumoniae (12.6%), Haemophilus 
influenzae (6%), Staphylococcus aureus (1.6%) and Moruxellu catarrhalis (1,6%).Atypical pathogens were frequently 
found, with the following distribution: Mycoplasma pneumoniae, 7.5 %; Chlamydia pneumoniae, 5.3%; and Legionella 
pneumophila, 4.4%. The mean duration between onset of symptoms and hospital admission was 4.8 days, and the 
mean treatment duration was 12.1 days.Two weeks after the start of therapy, although clinical symptoms were absent, 
radiologic infiltrates were still present in 24% of patients. 
Conclusions: The microbiological diagnosis in CAP can be established in only about 50% of cases with the 
combination of several diagnostic tools. Epidemiologic surveys of CAP should be performed on a regular basis, 
regionally, as a way to improve the management of these infections. 
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INTRODUCTION 
Respiratory infections are among the illnesses most 
frequently encountered by physicians in the USA and 
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Europe in both outpatient and hospital practice. In 
particular, community-acquired pneumonia (CAP) has 
an estimated annual incidence of 4 million cases among 
ambulatory patients, or 12 cases per 1000 persons in the 
USA. Pneumonia, in general, is the sixth leading cause 
of death in the USA, and is responsible for more than 
600 000 hospital admissions per year.l Mortality rates 
approximate 13.7% among all cases of CAP requiring 
hospital admission,2 and appear to be even higher in the 
elderly population. 
The most common microbes associated with CAP 
are Streptococcus pneumoniae, Haemophilus influenzae, 
and Mycoplasma pneumoniae.3-5 However, during the 
last decade, pathogens such as Moraxella catarrhalis, 
Legionella pneumophila and Chlamydia pneumoniae 
have been identified more frequently, and several studies 
have demonstrated the importance of these newly recog- 
nized pathogens.2 
Diagnosis of infections caused by atypical patho- 
gens is often limited by the lack of routine and easy-to- 
perform tests for these agents. In addition, the growing 
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incidence of p-lactam and/or macrolide resistance in 
common respiratory bacterial pathogens such as Strepto- 
coccus pneumoniae and Haemophilus influenzae com- 
plicates the selection of an appropriate antibiotic for 
initial empirical treatment. c9 Initial empirical therapy 
should inhibit Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, and atypical pathogens. 
The initial management of CAP requires a decision 
as to the need for patient hospitalization. In selected 
circumstances, the severity of illnesslo will necessitate 
hospital admission and the administration of intravenous 
antibiotics. Once the patient has improved, intravenous 
antibiotics may be replaced with oral agents, depending 
on the availability of an efficacious and safe oral agent 
to treat the infecting pathogen(s). 
We have performed a prospective, randomized, open- 
label, comparative, controlled study on CAP requiring 
hospitalization in Switzerland. 
The original study was a randomized, phase III, 
multicenter, blind (open when patient was included) 
study to compare the quinolone trovafloxacin 200 mg/day 
intravenously, and then orally once a day, with amoxi- 
cillin<lavulanic acid 4 x 1.2 g/day intravenously, and then 
orally with optional clarithromycin, for the treatment of 
CAP The intravenous treatment was given for a mini- 
mum of 48 h, followed by oral treatment, to complete at 
a course of treatment of at least 7 days. 
The purpose of this paper is to present the main 
epidemiologic features of patients with CAP requiring 
hospitalization in our country, and not to compare the 
results of the two different treatments. 
MATERIALS AND METHODS 
The study was a multicenter, prospective, randomized, 
blind (open-label when patient was included), compar- 
ative, controlled study conducted at seven Swiss medical 
centers (Basel-Bruderholz, Biel, Fribourg, Geneva, La 
Chaux-de-Fends, Saint-Gall, and Zoug). The institu- 
tional review board of each center approved the study, 
and all patients provided written informed consent. 
Patients who fulfilled inclusion criteria were ran- 
domized according to a computer-generated, blinded 
randomization list, and assigned to one treatment arm to 
complete at least 7 days of therapy. 
Patient characteristics 
Patients eligible for inclusion in the study met the 
following criteria: older than 18 years and hospitalized 
with a primary diagnosis of CAP; a medical and clinical 
history of pneumonia; a new pulmonary infiltrate 
revealed by chest X-ray compatible with pneumonia; 
and two or more signs and symptoms associated with a 
lower respiratory tract infection (i.e. body temperature 
>38”C or <36.1”C, new or increased cough, production 
of purulent sputum, findings on examination such as 
rales or evidence of pulmonary consolidation, blood 
leukocyte count >lO 000/mm3 or <4000/mm3, or >lO% 
bands, hypoxemia (defined as:p02 ~70 mmHg at FiOz= 
21% or a decrease of >25% from an initial value)). 
Patients excluded were: pregnant women, nursing 
mothers, or women of childbearing potential not prac- 
ticing adequate contraception; patients with known or 
suspected hypersensitivity or intolerance to the study 
drugs; and those who had received antimicrobial therapy 
for 24 h or longer within 72 h prior to the baseline visit, 
unless there was documented evidence of resistance 
or clinical failure. Also excluded were the following 
subjects: those with AIDS, suspected Pneumocytis 
carinii pneumonia, or a known infection with fungi or 
mycobacteria; those with neutropenia, defined as a total 
of white blood cells of less than 1000 leukocytes/mm3, or 
an absolute neutrophil count of less than 1000/mm3; 
those receiving immunosuppressive therapy, defined 
as chronic treatment with known immunosuppressive 
agents; those with a diagnosis of cystic fibrosis, known 
lung cancer, emphysema or aspiration pneumonia, cavi- 
tary lung diseases confirmed by chest X-ray at baseline, 
or a history of seizures; those who had received any 
investigational agent within the month prior to the base- 
line visit; those who had been enrolled in this study 
previously; those with evidence of recent drug or alcohol 
abuse or dependence; and those with an underlying 
condition that might give them a life expectancy <l week, 
or who had been hospitalized during the past week. 
Microbiological investigations 
From’all patients, a sputum specimen for routine culture 
and Gram stain was obtained prior to study entry. If 
a satisfactory specimen or expectorated sputum was 
not obtained, the investigator could carry out induction 
of sputum with nebulized hypertonic or physiotherapy 
or, if medically indicated, could use other techniques 
such as transtracheal aspiration, bronchoalveolar lavage, 
bronchial brushings, or biopsy. In addition, blood cultures 
were performed by standard procedures at study entry 
and during other visits, if clinically indicated. Identi- 
fication of causative organisms and testing for aerobic 
susceptibility to study drugs by disk and broth micro- 
dilution MIC methods was performed according to the 
National Committee for Clinical Laboratory Standards 
procedures. l1 Serologic testing for Mycoplasma pneu- 
moniae (complement fixation), L. pneumophila (enzyme- 
linked immunosorbent assay) and Chlamydia pneumoniae 
(microimmunofluorescence test) was performed in 
all patients at baseline and 4 weeks after study entry 
(results were positive when there was a fourfold rise 
in the titer of Ig or the Ig titer was >1/2.56 in a simple 
serum sample). A urine antigen assay for Legionella spp. 
was also performed at the time of admission (Binax, S. 
Portland, Maine, USA).i2 
Identification of typical and atypical pathogens 
was performed at the bacteriologic laboratories of the 
indicated centers, and, when necessary, by a reference 
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laboratory Standard respiratory pathogens, when isolated 
from purulent respiratory secretions, were considered 
to be the microorganism responsible for the infection. 
Throat swabs and sputum specimens were used at study 
entry for PCR assays for Mycoplasma pneumoniae 
(gene amplification with primers MPP 10 and MPP 12)13 
and Chlamydia pneumoniae (amplification by Pst with 
primers HM-1 and HR-1).14 
RESULTS 
Three hundred and twenty-three patients were enrolled 
during the 19-month study period (from November 
1997 to May 1999) at seven Swiss hospital centers. Five 
patients did not meet the entry criteria and were excluded 
from the study due to protocol violations (hospital- 
acquired pneumonia, bronchial aspiration pneumonia, 
acute bronchitis, and two cases of urinary sepsis). The 
numbers of patients included in the different centers 
were as follows: Basel-Bruderholz, 6; Biel, 60; Fribourg, 
51; Geneva, 102; La Chaux-de-Fonds, 42; Saint Gall, 47; 
and Zoug, 10. The total number of patients was 318. 
Study population 
The mean age of the adult patients was 70.4 years. 
Baseline demographic data are presented in Table 1. 
The most frequent underlying diseases present at 
study entry were cardiac failure (71, 23%) chronic 
obstructive pulmonary disease (63, 20%) renal failure 
(45, 15%) diabetes (39, 12%) asthma (17, 5%) and 
hepatic failure(16, 5%). One hundred and twenty-four 
patients (40%) were smokers.The mean time from onset 
of symptoms to admission was 4.8 days (SD 4.39) (median 
3.5). The mean total duration of treatment for clinically 
evaluable patients was 12.1 days (k4.95). 
The proportions of patients with different clinical 
symptoms and signs of pneumonia at study entry are 
presented in Table 1. 
The relatively low frequency of fever was probably 
due to the advanced age of the patients. The high mean 
age of the study population and the high percentage of 
co-morbidities allow the classification of patients as class 
III according to the Fine criteria.15 
Radiologic results 
The most common localization of radiologic infiltrates 
at study entry comprised lesions on the right lung (49%) 
with a significant difference (PcO.05) compared to local- 
ization on the left lung (34%). Bilateral infiltrates were 
found in 81 patients (18%). Pleural effusion was present 
in 86 patients (27%). Other radiologic data are shown in 
Table 2. 
Two weeks after the start of treatment, radiologic 
success (defined as resolution or improvement of ab- 
normal pre-therapy radiographic findings) was observed 
in 188 patients (76%) whereas radiologic failure (failure 
of resolution or improvement of abnormal pre-therapy 
radiographic findings) was observed at the same time in 
62 patients (24%). 
At the end of the study period (28 days after study 
entry), among evaluable patients, radiologic resolution 
(no abnormal radiographic findings) was observed in 
102, and persistence of radiologic infiltrates in 13. 
Bacteriologic findings 
One hundred and twenty-four pathogens (39%) were 
identified at baseline among the patients. The most 
common typical bacterial pathogens isolated from 
sputum specimens of the study population patients were 
Streptococcus pneumoniae (40), Haemophilus influenzae 
(19) Staphylococcus aureus (8), and Moraxella catarrhalis 
(5). Other microorganisms isolated from sputum cultures 
are listed in Table 3. For 28 patients, sputum could not 
Table 1. Patients’ demographic characteristics and clinical 
symptoms and signs of pneumonia at study entry 
Demographic 
Total number of patients 
Male (no. (%)) 
Female (no. (%)) 
Age (years) 
Patients over 65 years (no. (%)) 
Body weight (kg) 
Height (cm) 
Signs and symptoms (no. (%)) 
Pulmonary auscultation findings 
Cough 
Dyspnea 
Respiratory rate 
r20/min 
r30/min 
Increased sputum volume 
Temperature ~38°C 
Heart rate r95/min 
Chills 
Pleuritic chest pain 
Pleural effusion 
318 
188 (59%) 
130 (41%) 
70.4 (216.2) 
212 (67%) 
80 (37-l 23) 
168.5 (145-195) 
291 (92%) 
287(90%) 
280(88%) 
249(78%) 
95(30%) 
215(68%) 
202(64%) 
173 (54%) 
173 (54%) 
168(53%) 
86(27%) 
Table 2. Radiologic findings in the study population at study 
entry 
Number % 
Presence of lung infiltrates (n=478) 
In right lung 235 49 
In left lung 162 34 
Bilateral lung 81 17 
In right lung lobes (n=308) 
Lower 138 45 
Middle 77 25 
upper 55 18 
Bi-lobe 34 11 
Tri-lobe 4 1 
In left lung lobes (n= 170) 
Lower 126 74 
Upper 31 18 
Both 13 8 
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Table 3. Respiratory tract pathogens detected by sputum 
culture and nonculture methods in the study population 
Number of 
Microorganisms patients Percentage 
Streptococcus pneumoniae 40 12.6 
Haemophilus influenzae 19 6.0 
Mycoplasma pneumoniae 24 7.5 
Chlamydia pneumoniae 8 2.5 
Legionella spp. 17 5.3 
Staphylococcus aureus 14 4.4 
Moraxella catarrhalis 5 1.6 
Klebsiella pneumoniae 2 0.6 
Streptococcus beta-haemolyticus 1 0.3 
Mycobacterium (non-tuberculosis) 1 0.3 
Pasteurella multocida 1 0.3 
nor L. pneumophila, seven serology conversion, six cases diagnosed by 
positive urinary antigen, and one by culture. 
For Mycoplasma pneumoniae, seven serology conversion and 17 
diagnosed by PCR. 
For Chlamydia pneumoniae, nine serology conversion and eight diagnosed 
by PCR. 
be obtained at study entry. No penicillin-, erythromycin- 
or clarithromycin-resistant isolates of Streptococcuspneu- 
moniae were identified. 
Other microorganisms isolated from sputum cultures 
at study entry which are not usually considered to be 
respiratory pathogens were: Pseudomonas aeruginosa, 
Escherichia coli, Enterobacter cloacae, Acinetobacter spp., 
Corynebacterium diphtheriae, Pseudomonas fluorescens, 
Stenotrophomonas maltophilia, Serratia marcescens, 
Enterobacter aerogenes, Hafnia alvei, Candida albicans, 
and Aspergillusfimigatus. None of the patients was sub- 
jected to invasive techniques to obtain sputum samples. 
Serologic samples were taken from 83% (264) of 
the patients at study entry, and from 53% (169) patients 
4 weeks later for serology control. 
Legionella urinary antigen testing was performed in 
95 % of the patients at study entry, and was positive in six 
cases. Positive PCR in throat specimens was observed in 
17 cases for Mycoplasma pneumoniae, and in eight cases 
for Chlamydia pneumoniae. An etiologic diagnosis of 
CAP was possible in 130 patients (41%).The overall mor- 
tality rate at 30 days in this patient population was 8%. 
Blood cultures 
At study entry, 56 (19.2%) patients had positive blood 
cultures. The most common bacterial pathogens iso- 
lated from blood cultures and presumed to be involved 
in the etiology of pneumonia were: Streptococcus 
pneumoniae (n=32) (10%) (57% of all positive blood 
cultures), Haemophilus infiuenzae, Staphylococcus 
aureus, Escherichia coli (n=3) (5.3%), Morganella 
morganii, and Streptococcus agalactiae (n=l) (1.8%). 
Other microorganisms isolated without evidence of 
a pathogenic role in pneumonia or considered to be 
contaminants were coagulase-negative Staphylococcus 
(n=7), Propionibacterium spp. (n=2) and, with one case 
each, Enterococcus aerogenes, Pseudomonas pan&noli, 
Streptococcus mitis, and Oligella urethralis. 
Analysis of all microorganisms isolated from blood 
cultures (56) and all microorganisms isolated from 
sputum (124) showed that matching of similar patho- 
gens (blood cultures/sputum) was achieved in only nine 
cases. In 29 cases with positive blood cultures, no micro- 
organisms were found in sputum. Finally, in 18 cases with 
positive blood cultures, the microorganisms isolated in 
sputum were different but did not fit the standard 
purulent criteria with Gram stain. These results demon- 
strate the importance of blood cultures for the establish- 
ment of the etiology of CAP, and give an indication of 
how frequently blood or sputum samples may con- 
taminate pathogens. 
DISCUSSION 
CAP is a common condition, and its treatment poses 
new challenges because of the growing incidence of 
antibiotic resistance among traditional respiratory 
pathogens and the increasing recognition of pneumonia 
caused by atypical respiratory pathogens.16 
Rapid diagnosis of the etiologic agents causing 
respiratory infections is difficult, and the treatment of 
patients with CAP is often empiricaLTherefore, selection 
of an appropriate antibacterial agent should be, in large 
part, based on its antimicrobial activity and the local 
epidemiologic setting. Local sensitivity patterns need to 
be considered in particular, because there are different 
rates of pneumococci penicillin resistance in different 
countries. 
In this study, we achieved a precise etiology for the 
causative pathogens, with the use of different diagnostic 
techniques such as sputum culture, PCR, serology, blood 
cultures, and Legionella urine antigen, in a total of 41% 
of the study population. The etiology was unknown for 
the other patients, but this proportion is comparable 
with the results of other studies.2J7 Antibiotics given 
before admission probably decreased the possibility of 
isolating a specific pathogen, even though antibiotic 
treatment was administered for less than 24 h in our 
study. 
The most frequent typical respiratory pathogens 
isolated were: Streptococcus pneumoniae (the pre- 
dominant pathogen in our study, as in other published 
studies2Js.19), Haemophilus influenzae, Staphylococcus 
aureus, Moraxella catarrhalis, and Klebsiella pneumoniae. 
Infection rates with the three atypical pathogens 
Chlamydia pneumoniae, Legionella pneumophila and 
Mycoplasma pneumoniae were comparable to those in 
the series published by Halm et a1,20 but lower than in 
other series.lJ 
In the present study, we did not observe antibiotic 
resistance of Streptococcus pneumoniae, as reported 
elsewhere.9 The resistance of Streptococcus pneumoniae 
in the Alexander project during the same period ranged 
between 3% and 6% in Switzerland (from 1996 to 1999). 
The absence of resistant pneumococci in our patients is 
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probably due to differences between overall specimen 
collection in some large microbiological centers when 
compared to our prospective clinical study. 
In some other European countries, such as Italy, 
Austria and Belgium, the frequency of resistance in 
Streptococcus pneumoniue remains quite low, but not in 
France or Greece, where it was much higher during the 
same time period (32-40%). In the study by Plouffe et 
al,** from the USA, incidences of 8% of Streptococcus 
pneumoniue resistance to penicillin and 2.8% to ofloxacin 
were reported. We did not observe Streptococcus pneu- 
moniue resistance to erythromycin and clarithromycin, 
whereas in another study, performed in Providence 
(USA), 5% of isolates of Streptococcus pneumoniae 
from bacteremic patients were resistant to erythromycin 
and clarithromycin.23 
The most common localization of radiologic in- 
filtrates comprised lesions on the right lung, with signi- 
ficant differences to localization on the left lung. Bilateral 
infiltrates were found in 81 patients. Radiologic resolution 
was not observed in 13 patients. 
The studies listed in Table 4 were comparable to the 
present study. They were multicenter and randomized 
studies with similar sample sizes. Most of the studies 
were performed in North America; therefore, it is 
Table 4. Comparison with other studies 
interesting to have recent epidemiologic data from 
Switzerland. Some of these studies looked for concomi- 
tant diseases, clinical signs and clinical symptoms at study 
entry. In our patient population, the most important 
differences, compared to these other studies, were a 
higher patient mean age, a higher proportion of smokers, 
and a more accurate description of respiratory symptoms 
and clinical signs. In our series, careful auscultation 
revealed positive signs in 92% of the cases. By contrast, 
fever was observed in only 64% of cases. 
The mortality rate of 8% among our hospitalized 
patients was lower than those previously reported in 
most other studies,* despite the fact that the severity of 
disease and the age at hospitalization were high. This 
probably reflects a better standard of care, and perhaps 
earlier treatment in the ambulatory setting preventing a 
progressive severe infection. The microbiological diag- 
nosis in CAP can only be established in about 50% of 
cases. In spite of the combined use of several diagnostic 
tools, about 50% of patients are treated with no identi- 
fication of the microorganisms involved. We recommend 
that epidemiologic surveys of CAP should be performed 
on a regular basis, regionally, as a way to improve 
the management of these frequent infections requiring 
hospitalization. 
Sarbino, Mandell and Halm 
present report Donowitz24 et a12* 
Fang 
et al2 
Plouffe 
et alzl 
File 
et all7 
Bartlett 
and Mundy’ 
Study design 
Multicenter 
Randomized 
X 
X 
Mean age (years) 70 
Number of patients 318 
Etiology 
Known etiology (%) 
Positive blood cultures (%) 
Streptococcus pneumoniae (%) 
Haemophilus influenzae (%) 
Gram-negative pathogens (%) 
Atypical pathogens (%) 
41 
17.6 
12 
6 
7.9 
4 
Concomitant diseases 
COPD (%) 
Cardiac failure (%) 
Renal failure (%) 
Diabetes (%) 
Hepatic failure (%) 
Smoker (%) 
Asthma (%) 
19.8 
22 
14.1 
12.2 
5 
38.9 
5 
Symptoms (%) 
Heart rate >95/min 
: Temperature >38”C 
Respiratory rate >25/min 
Cough 
Dyspnea 
Chills 
Pleural effusion 
Increased sputum production 
Pulmonary auscultation \ 
55 
64 
78 
90 
88 
54 
27 
68 
92 
50-60 58 
50-70 27 
16-60 
4-15 
7-18 
I-10 
45 
68-78 
69 
80 
40-50 
20 
.60-80 
X 
X 
X 
X 
X 
X 
X 
X 
C’OPD, chronic obstructive pulmonary disease. 
21 
19 
8 
13 
9 
56 
46 
71 
63 57-58 50 
359 298 456 
37 
7.70 
15.3 
10.9 
5.9 
31.4 
29 
7 
45.1 
47.2 
88.4 
60.2 
47.8 
70.8 
64 46 
8 13.5 
10 11.2 
26 
35-70 
11 
5-18 
3-18 
3-10 
1 O-20 
80 
>85 
49.4 
57.8 
49.4 
30-50 
67.9 
80 
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